USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Altea Therapeutics Corporation
Address:
Altea Therapeutics Corporation
2056 Weems Road
Tucker, GA 30084
Phone:
(678) 495-3108
URL:
N/A
EIN:
593538644
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $403,662.00 5
SBIR Phase II $1,173,511.00 2

Award List:

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$99,442.00
Agency:
HHS
Principal Investigator:
Harry K. Delcher
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$97,910.00
Agency:
HHS
Principal Investigator:
Harry K. Delcher
Abstract:
N/a

NEEDLE FREE INSULIN INFUSION WITH THERMAL MICROPORATION

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of this proposal over Phase I and II SBIR studies and subsequent full scale development is to commercialize a noninvasive insulin infusion system that is painless, convenient, discrete, safe, efficacious and cost-effective. Such a system will bridge the gap between the tight glucose control… More

NEEDLE FREE INSULIN INFUSION WITH THERMAL MICROPORATION

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$391,878.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of this proposal over Phase I and II SBIR studies and subsequent full scale development is to commercialize a noninvasive insulin infusion system that is painless, convenient, discrete, safe, efficacious and cost-effective. Such a system will bridge the gap between the tight glucose control… More

RAPID TRANSDERMAL DELIVERY OF OPIOID PAIN MEDICATIONS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$105,650.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The American Medical Association reports that undertreatment of pain is a major problem for cancer patients as well as for other disease conditions. Approximately 50-75% of cancer patients have pain that is undertreated, and 25% die in severe unrelieved pain.… More

Transdermal Hydromorphone for Acute and Chronic Pain

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$781,633.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Founded in 1998, Altea Therapeutics is developing its PassPort(tm) system to deliver proteins and peptides, small-molecule drugs, genes and vaccines from a skin patch, eliminating the need for invasive needle injection. This breakthrough technology, currently… More

Non-Invasive Drug Delivery by Thermal Microporation

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,660.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Founded in 1998, Altea Therapeutics is developing its PassPort(tm) transdermal drug delivery system to deliver proteins and peptides, small-molecule drugs, genes and vaccines from a skin patch, eliminating the need for invasive needle injection. This… More